Gasparini M, Lombardi F, Gianni C, Lattuada A, Rilke F, Fossati-Bellani F
Am J Pediatr Hematol Oncol. 1983 Summer;5(2):161-71.
Seventy-nine consecutive children with non-Hodgkin's lymphoma were treated with a uniform intensive radiotherapy-chemotherapy program including high-dose MTX and CNS prophylaxis. Burkitt-type NHL was diagnosed in 44% and convoluted cell-type NHL in 33%. Complete remission rate was 97.5%. Forty-eight of 79 children (61%) remain progression-free after 18-78 months of follow-up. Patients belonging to the Burkitt type subgroup showed a peculiar clinical behavior as well as a significantly shorter survival than the other NHL patients (3-year overall survival rates of 50% vs. 72%, respectively). Clinical stages were related to the progression-free survival. It is concluded that treatment should be tailored according to the histology (Burkitt-type NHL vs. other histologic types) and the clinical stage.
79例连续的非霍奇金淋巴瘤患儿接受了包括大剂量甲氨蝶呤和中枢神经系统预防的统一强化放疗-化疗方案。44%的患儿被诊断为伯基特型非霍奇金淋巴瘤，33%为卷曲细胞型非霍奇金淋巴瘤。完全缓解率为97.5%。79例患儿中有48例（61%）在18至78个月的随访后仍无疾病进展。伯基特型亚组的患者表现出特殊的临床行为，并且生存期明显短于其他非霍奇金淋巴瘤患者（3年总生存率分别为50%和72%）。临床分期与无进展生存期相关。结论是治疗应根据组织学类型（伯基特型非霍奇金淋巴瘤与其他组织学类型）和临床分期进行个体化调整。
